Ana Laura Ortega Selected Research

Programmed Cell Death 1 Receptor

1/2023

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ana Laura Ortega Research Topics

Disease

10	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 01/2019
4	Lung Neoplasms (Lung Cancer) 12/2023 - 03/2021
2	Neoplasms (Cancer) 01/2023 - 06/2021
1	Fatigue 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Proteinuria 01/2023
1	Pruritus (Itching) 01/2023
1	Epilepsy (Aura) 03/2021
1	Brain Neoplasms (Brain Tumor) 06/2019

Drug/Important Bio-Agent (IBA)

2	Biomarkers (Surrogate Marker)IBA 07/2022 - 06/2021
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2019
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2019
1	durvalumabIBA 03/2024
1	olaparibIBA 12/2023
1	PlatinumIBA 12/2023
1	atezolizumabIBA 01/2023
1	Bevacizumab (Avastin)FDA Link 01/2023
1	Drug CombinationsIBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	osimertinibIBA 03/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 06/2019
1	Etoposide (VP 16)FDA LinkGeneric 01/2019

Therapy/Procedure

3	Therapeutics 03/2024 - 01/2021
1	Chemoradiotherapy 03/2024
1	Radiotherapy 01/2021